Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across eight U.S. sites.
Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.
CAAR-T therapy may eliminate FVIII inhibitors in hemophilia A, potentially improving replacement treatment effectiveness, a study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results